Journal article

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2 alpha/Ribavirin

Tarik Asselah, Alex J Thompson, Robert Flisiak, Manuel Romero-Gomez, Diethelm Messinger, Georgios Bakalos, Mitchell L Shiffman

PLOS ONE | PUBLIC LIBRARY SCIENCE | Published : 2016

Grants

Funding Acknowledgements

These studies were funded by F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche participated in the design and conduct of the study, in the analysis and interpretation of the data, and in the preparation and review of the manuscript before submission. Third-party medical writing assistance, provided by Blair Jarvis MSc, ELS, of Health Interactions, but not editorial content development sufficient to meet International Committee of Medical Journal Editors (ICMJE) authorship criteria, was provided by Health Interactions and funded by F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd provided support in the form of salaries for authors [GB]. PROMETRIS GmbH is the clinical research organization contracted by F. Hoffmann-La Roche Ltd to provide data management and statistical services. PROMETRIS GmbH provided support in the form of salaries for authors [DM], participated in the design and conduct of the study, in the analysis and interpretation of the data, and in the preparation and review of the manuscript before submission. The specific roles of these authors are articulated in the 'author contributions' section.Support for third-party writing assistance for this manuscript, provided by Debbie Briggs PhD and Blair Jarvis Msc, ELS of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland.